A Phase 3 interventional study of ibuprofen and acetaminophen in Fever, sponsored by Cumberland Pharmaceuticals. Completed at 17 sites in United States. Open to participants aged Up to 16 Years. Per ClinicalTrials.gov, last updated 2016-11-07.
Sponsored by Cumberland Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing ibuprofen in Fever — none open to participants now, none under way, none of them phase 3. Ibuprofen · Fever.
Among the 19 studies testing ibuprofen in Fever, this one is the 10th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2010, is one of 6 in phase 3, and was the 6th registered.
438 studies on the registry are indexed under Fever; 55 are open to participants now.
Browse Fever studies →None of the 19 studies testing ibuprofen in Fever is open now. The open studies under Fever, anywhere →
Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 38 Fever studies recruiting now, 18 (47%) set no upper age limit and 14 (37%) stop at 75 or younger; 22 take children under 18; 11 take healthy volunteers.
This study: Up to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 118 is close to the median of 123 across 271 interventional studies indexed under Fever.
Median enrollment 119 across the 18 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
Cumberland Pharmaceuticals is the lead sponsor of 49 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Cumberland Pharmaceuticals has 5 studies filed under Fever — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing ibuprofen in Fever, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to determine the superiority of a single dose of intravenous ibuprofen compared to acetaminophen for the treatment of fever during the first two hours of treatment.
The primary objective of the study is to determine the superiority of a single dose of intravenous ibuprofen compared to acetaminophen for the treatment of fever as measured by the area under the change in temperature versus time curve during the first 2 hours of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ibuprofen, 10 mg/kg
Drug: ibuprofen
Acetaminophen, 10mg/kg
Drug: acetaminophen
Ibuprofen, 10 mg/kg
Acetaminophen, 10mg/kg
Also known as: APAP (acetaminophen), paracetamol
Fever Reduction
Treatment of fever as measured by the area under the change in temperature versus time curve during the first two hours of treatment (AUC0-2)
Time frame: 0 to 2 hours post-dose
Change From Baseline in Temperature After the First 30 Minutes of Treatment
Change in temperature in patients receiving intravenous ibuprofen and acetaminophen (APAP) after the first 30 minutes of treatment.
Time frame: 30 minutes following treatment
Change From Baseline in Temperature After the First 60 Minutes of Treatment
Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 60 minutes of treatment.
Time frame: 60 minutes following treatment
Change in Temperature
Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 4 hours of treatment.
Time frame: 4 hours following treatment
Change From Baseline in Temperature After the First Four Hours of Treatment
Change in temperature during the first 4 hours of treatment by assessing the area under the change in temperature versus time curve during the first four hours of treatment (AUC0-4)
Time frame: 0 to 4 hours post-dose
Time to Afebrility (in Hours)
Tme to afebrility (temperature less than 100.4 ºF \[38 ºC\]) in patients receiving intravenous ibuprofen and APAP.
Time frame: 4 Hour post treatment
Number of Afebrile and Febrile Subject at 4 Hours Post-Dose
Number of Afebrile and Febrile Subject at 4 Hours Following Treatment
Time frame: 4 Hours Post-Dose
| Milestone | Ibuprofen | Acetaminophen |
|---|---|---|
| Started | 58 | 60 |
| Completed | 47 | 53 |
| Not completed | 11 | 7 |
| Withdrew: Subject did not receive at least 1 dose | 11 | 7 |
Treatment of fever as measured by the area under the change in temperature versus time curve during the first two hours of treatment (AUC0-2)
| degree Celsius*Time | Ibuprofen | Acetaminophen |
|---|---|---|
| Fever Reduction | -1.5 ± 1.11 | -0.9 ± 0.89 |
Change in temperature in patients receiving intravenous ibuprofen and acetaminophen (APAP) after the first 30 minutes of treatment.
| Celsius | Ibuprofen | Acetaminophen |
|---|---|---|
| Change From Baseline in Temperature After the First 30 Minutes of Treatment | -0.5 ± 0.50 | -0.3 ± 0.49 |
Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 60 minutes of treatment.
| Celsius | Ibuprofen | Acetaminophen |
|---|---|---|
| Change From Baseline in Temperature After the First 60 Minutes of Treatment | -0.9 ± 0.69 | -0.5 ± 0.50 |
Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 4 hours of treatment.
| Celsius | Ibuprofen | Acetaminophen |
|---|---|---|
| Change in Temperature | -1.5 ± 0.92 | -0.9 ± 0.92 |
Change in temperature during the first 4 hours of treatment by assessing the area under the change in temperature versus time curve during the first four hours of treatment (AUC0-4)
| degree Celsius*Time | Ibuprofen | Acetaminophen |
|---|---|---|
| Change From Baseline in Temperature After the First Four Hours of Treatment | -4.4 ± 2.59 | -2.6 ± 2.02 |
Tme to afebrility (temperature less than 100.4 ºF \[38 ºC\]) in patients receiving intravenous ibuprofen and APAP.
| Hours | Ibuprofen | Acetaminophen |
|---|---|---|
| Time to Afebrility (in Hours) | 2.2 ± 0.47 | 3.3 ± 0.67 |
Number of Afebrile and Febrile Subject at 4 Hours Following Treatment
| participants | Ibuprofen | Acetaminophen |
|---|---|---|
| Afebrile Subjects at 4 hours | 43 | 40 |
| Febrile at 4 Hours | 3 | 11 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibuprofen | — | 2/47 (4.3%) | 28/47 (59.6%) |
| Acetaminophen | — | 2/53 (3.8%) | 22/53 (41.5%) |
| Event | Ibuprofen | Acetaminophen |
|---|---|---|
| PancreatitisGastrointestinal disorders | 1/47 | 0/53 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/47 | 0/53 |
| Cardio-Respiratory ArrestCardiac disorders | 1/47 | 0/53 |
| Transaminases IncreasedInvestigations | 1/47 | 0/53 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 0/47 | 1/53 |
| Abdoimnal AbscessInfections and infestations | 0/47 | 1/53 |
| Event | Ibuprofen | Acetaminophen |
|---|---|---|
| Infusion Site PainGeneral disorders | 5/47 | 0/53 |
| DiarrhoeaGastrointestinal disorders | 1/47 | 4/53 |
| VomitingGastrointestinal disorders | 3/47 | 3/53 |
| NauseaGastrointestinal disorders | 3/47 | 2/53 |
| HeadacheNervous system disorders | 3/47 | 1/53 |
| Blood Lactate Dehydrogenase IncreasedInvestigations | 1/47 | 3/53 |
| Aspartate Aminotransferase IncreasedInvestigations | 2/47 | 2/53 |
| Alanine Aminotransferase IncreasedInvestigations | 2/47 | 1/53 |
| Blood Albumin DecreasedInvestigations | 2/47 | 0/53 |
| Oxygen Saturation DecreasedInvestigations | 2/47 | 0/53 |
All Treated Subjects
| Age, Customized(participants) | Ibuprofen | Acetaminophen | Total |
|---|---|---|---|
| 6 months to 2 years | 6 | 14 | 20 |
| 2 years to 6 years | 13 | 14 | 27 |
| 6 years to 16 years | 28 | 25 | 53 |
| Sex: Female, Male(Participants) | Ibuprofen | Acetaminophen | Total |
|---|---|---|---|
| Female | 20 | 27 | 47 |
| Male | 27 | 26 | 53 |
| Ethnicity (NIH/OMB)(Participants) | Ibuprofen | Acetaminophen | Total |
|---|---|---|---|
| Hispanic or Latino | 29 | 24 | 53 |
| Not Hispanic or Latino | 18 | 29 | 47 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ibuprofen | Acetaminophen | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 8 | 13 |
| White | 42 | 42 | 84 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
The record gives a start of Jul 2010, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 3 years 5 months after primary completion. A results delay was requested in Jul 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen